Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

被引：5
|
作者：
Usmani, Saad Z. [1 ]
Dimopoulos, Meletios A. [2 ]
Belch, Andrew [3 ]
White, Darrell [4 ]
Benboubker, Lofti [5 ]
Cook, Gordon [6 ,7 ]
Leiba, Merav [8 ]
Morton, James [9 ]
Ho, P. Joy [10 ]
Kim, Kihyun [11 ]
Takezako, Naoki [12 ]
Khokhar, Nushmia Z. [13 ]
Guckert, Mary [13 ]
Wu, Kaida [13 ]
Qin, Xiang [13 ]
Casneuf, Tineke [14 ]
Chiu, Christopher [13 ]
Sasser, A. Kate [13 ]
San-Miguel, Jesus [15 ]
机构：
[1] Levine Canc Inst Carolinas HealthCare Syst, Charlotte, NC USA
[2] Univ Athens, Athens, Greece
[3] Univ Alberta Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada
[4] Dalhousie Univ, QEII Hlth Sci Ctr, Halifax, NS, Canada
[5] Ctr Hosp Regional Univ CHRU, Serv Hematol & Therapie Cellulaire, Hop Bretonneau, Tours, France
[6] Leeds Teaching Hosp NHS Trust, St Jamess Inst Oncol, Leeds, W Yorkshire, England
[7] Univ Leeds, Leeds, W Yorkshire, England
[8] Sheba Med Ctr, Tel Hashomer, Israel
[9] Icon Canc Care, South Brisbane, Qld, Australia
[10] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW, Australia
[11] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, Seoul, South Korea
[12] Natl Hosp Org Disaster Med Ctr Japan, Dept Hematol, Tachikawa, Tokyo, Japan
[13] Janssen Res & Dev, LLC, Spring House, PA USA
[14] Janssen Res & Dev, Beerse, Belgium
[15] Clin Univ Navarra CIMA, IDISNA, Pamplona, Spain
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1151.1151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1151
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
    Plesner, Torben
    Dimopoulos, Meletios A.
    Oriol, Albert
    San-Miguel, Jesus
    Bahlis, Nizar J.
    Rabin, Neil
    Suzuki, Kenshi
    Yoon, Sung-Soo
    Ben-Yehuda, Dina
    Cook, Gordon
    Goldschmidt, Hartmut
    Grosicki, Sebastian
    Qin, Xiang
    Fastenau, John
    Garvin, Wendy
    Carson, Robin
    Renaud, Thomas
    Gries, Katharine S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (01) : 132 - 139
  • [32] Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial
    Maiese, Eric M.
    Graham, Christopher N.
    Hawe, Emma
    Le Moine, Jean-Gabriel
    Abraham, Ivo
    Senbetta, Mekre
    BLOOD, 2017, 130
  • [33] Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
    Wong, Xin Yi
    Chng, Wee Joo
    Aziz, Mohamed Ismail Abdul
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 207 - 215
  • [34] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [35] Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
    Bahlis, Nizar
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Krevvata, Maria
    Chiu, Christopher
    Qin, Xiang
    Okonkwo, Linda
    Trivedi, Sonali
    Qi, Ming
    San-Miguel, Jesus F.
    BLOOD, 2018, 132
  • [36] Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Palumbo, Antonio
    Lisby, Steen
    Basse, Linda
    Wang, Jianping
    Sasser, A. Kate
    Guckert, Mary E.
    de Boer, Carla
    Khokhar, Nushmia Z.
    Yeh, Howard
    Clemens, Pamela L.
    Ahmadi, Tahamtan
    Lokhorst, Henk M.
    Richardson, Paul G.
    BLOOD, 2016, 128 (14) : 1821 - 1828
  • [37] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    Siegel, D. S.
    Richardson, P.
    Dimopoulos, M.
    Moreau, P.
    Mitsiades, C.
    Weber, D.
    Houp, J.
    Gause, C.
    Vuocolo, S.
    Eid, J.
    Graef, T.
    Anderson, K. C.
    BLOOD CANCER JOURNAL, 2014, 4 : e182 - e182
  • [38] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    D S Siegel
    P Richardson
    M Dimopoulos
    P Moreau
    C Mitsiades
    D Weber
    J Houp
    C Gause
    S Vuocolo
    J Eid
    T Graef
    K C Anderson
    Blood Cancer Journal, 2014, 4 : e182 - e182
  • [39] CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Ri, M.
    Suzuki, K.
    Chou, T.
    Sugiura, I.
    Takezako, N.
    Sunami, K.
    Ishida, T.
    Izumi, T.
    Ozaki, S.
    Iida, S.
    HAEMATOLOGICA, 2016, 101 : 787 - 788
  • [40] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    Nature Clinical Practice Oncology, 2008, 5 : 374 - 375
12345